Next generation in worldwide treatment of infection and disease

The platform is based on the underlying pharmaceutical activity of CarboHydrate Derived Fulvic Acid (CHD-FA). Having a common safety and toxicity profile, with completed Phase 1 studies in humans for both topical and ingested use, CHD-FA is ideally positioned to enter Phase 2 studies for whatever indication efficacy has been demonstrated.

Image title

Topical – Phase 2

  • Alcohol and chlorhexadine free mouthwash
  • Drug resistant wound infection gel
  • Vaginal cream for both vaginitis and vaginosis

Ingested – Phase 2

  • Type 2 diabetes
  • CA-MRSA and HA-MRSA
  • NDM1 infection
  • Clostridium infection
  • Multi – species Candida infection